Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Anidulafungin (Eraxis) vs Vasopressin (Vasostrict)
An educational, source-based comparison of Anidulafungin (Eraxis) and Vasopressin (Vasostrict) — how each peptide works, what it's researched for, and what to know before going deeper.
Echinocandin lipopeptide for invasive Candida infections.
Semisynthetic lipopeptide that non-competitively inhibits β-(1,3)-D-glucan synthase, disrupting fungal cell wall synthesis in Candida and Aspergillus species.
- Candidemia and other invasive candidiasis
- Esophageal candidiasis
- • FDA-approved.
- • No dose adjustment for renal/hepatic impairment.
- • Infusion-related reactions possible.
Endogenous nonapeptide that activates V1 vascular receptors to cause vasoconstriction and V2 renal receptors for water reabsorption. Used to raise blood pressure in catecholamine-resistant shock.
- Septic shock
- Cardiac arrest (historical)
- Diabetes insipidus
- • FDA-approved.
- • Ischemic complications possible at high doses.
Anidulafungin (Eraxis) vs Vasopressin (Vasostrict) — Key differences
- Class: Anidulafungin (Eraxis) is classified as Echinocandin · Antifungal, while Vasopressin (Vasostrict) is Vasopressor · Hormonal.
- Primary research focus: Anidulafungin (Eraxis) — candidemia and other invasive candidiasis; Vasopressin (Vasostrict) — septic shock.
- Tag: FDA-Approved · Antifungal vs FDA-Approved · Critical Care.